Cover Image

Effectiveness and Safety of Mepolizumab in Allergic Bronchopulmonary Aspergillosis ( ABPA ): Real‐World Experience From a Chinese Retrospective Case Series

Fuente: Wiley Open Access

Saved in:

Bibliographic Details
Main Authors:	Xu Li, Peize Liu, Tingting Gao, Jingjing Wang, Mengwei Wu, Haoyuan Li, Yinghui Qu, Ruichen Du, Liang Dong, Qian Qi, Lili Zhi
Format:	Artículo Open Access
Published:	Wiley 2025
Subjects:	Clinical & Experimental Allergy
Online Access:	Acceder al recurso
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Clinical Characteristics of Difficult‐To‐Treat Allergic Bronchopulmonary Aspergillosis and Its Prediction Score
by: Jun Tanaka, et al.
Published: (2025)

Optimal ImmunoCAP Aspergillus fumigatus ‐Specific IgE Threshold for Detecting Allergic Bronchopulmonary Aspergillosis in Adults With Asthma: A Diagnostic Accuracy Study
by: Ritesh Agarwal, et al.
Published: (2025)

Efficacy and Safety of Mepolizumab 300 mg in Eosinophilic Granulomatosis With Polyangiitis: A Meta‐Analysis of Eight Retrospective Studies
by: Federico Spataro, et al.
Published: (2025)

Long‐Term, Real‐World Effectiveness of Allergen Immunotherapy in Children and Adolescents With Allergic Rhinitis and Asthma
by: Christian Woehlk, et al.
Published: (2025)

Letter to the Editor Regarding “Do Skin Prick Tests Predict Nasal Provocation Test Outcomes in Allergic Rhinitis Patients?”
by: Xu Li, et al.
Published: (2025)

Chinese Position Paper on Biologic Therapy for Allergic Rhinitis
by: Yuan Zhang, et al.
Published: (2026)

Real‐World Efficacy and Safety of Abrocitinib in Chinese Atopic Dermatitis Patients: A Single‐Center Prospective Study
by: Zheng Li, et al.
Published: (2025)

Bioactive Mediator Profile of Mepolizumab‐Treated Eosinophilic Granulomatosis With Polyangiitis
by: Yosuke Kamide, et al.
Published: (2024)

International Evidence‐Based Guidelines for Traditional Chinese Medicine Management of Allergic Rhinitis
by: Qin‐Wei Fu, et al.
Published: (2025)

Multiomic Integration Analysis for Monitoring Severe Asthma Treated With Mepolizumab or Omalizumab
by: Nuria Contreras, et al.
Published: (2024)

Effectiveness and Predictors of House Dust Mite Subcutaneous Immunotherapy in Polysensitised Patients With Allergic Rhinitis: A Multicentre Retrospective Study
by: Zhouxian Pan, et al.
Published: (2026)

Real‐World Efficacy and Safety of Dupilumab Retreatment in Adults With Relapsed Atopic Dermatitis: A Retrospective Study From China
by: Anda Zhang, et al.
Published: (2025)

Cost‐Effectiveness of Allergen Immunotherapy for Allergic Rhinitis: A Systematic Review
by: Joshua Jacob, et al.
Published: (2026)

High‐Dimensional Analysis of Type 2 Lymphocyte Dynamics During Mepolizumab or Dupilumab Treatment in Severe Asthma
by: Lorenz Wirth, et al.
Published: (2025)

Superior Benefits of Combining Mepolizumab With Sinus Surgery Compared to Mepolizumab Alone: Results From a Randomised 6‐Month Trial
by: Anne‐Sophie Homøe, et al.
Published: (2025)

Protein Glycosylation: An Emerging Regulator of Allergic Diseases
by: Pan Li, et al.
Published: (2025)

Comment on “Superior Benefits of Combining Mepolizumab With Sinus Surgery Compared to Mepolizumab Alone: Results From a Randomised 6‐Month Trial”
by: Yi Deng, et al.
Published: (2025)

Availability and Costs of Allergic Rhinitis Treatments Across the World: A Survey of ARIA Experts
by: Maria Clara Urbano, et al.
Published: (2026)

Upadacitinib for Refractory Paediatric Atopic Dermatitis: A Real‐World Study on Effectiveness and Safety in Dupilumab Nonresponders
by: Mutong Zhao, et al.
Published: (2024)

Real‐World Effectiveness and Safety of JAK Inhibitors in Atopic Dermatitis: A Systematic Review and Meta‐Analysis
by: Yunha Kim, et al.
Published: (2025)

Pollen‐Pharmacotherapy Interaction Impacts Symptom Control in Seasonal Allergic Rhinitis
by: Zengxiao Zhang, et al.
Published: (2026)

Real‐World Effectiveness for Sublingual Allergen Immunotherapy Among School‐Aged Children and Adolescents
by: Yusuke Okubo, et al.
Published: (2025)

Response to the Letter to the Editor by Deng and Lv Regarding “Superior Benefits of Combining Mepolizumab With Sinus Surgery Compared to Mepolizumab Alone: Results From a Randomised 6‐Month Trial”
by: Anne‐Sophie Homoe
Published: (2025)

Three‐Year Longitudinal Evaluation of Timing Effects on Subcutaneous Immunotherapy Efficacy and Safety in Allergic Rhinitis
by: Hang Li, et al.
Published: (2025)

Efficacy and Safety of Biologics for Chronic Rhinosinusitis With Nasal Polyps: A Meta‐Analysis of Real‐World Evidence
by: Shiru Cai, et al.
Published: (2025)

Interactive Effects of Ambient Fine Particulate Matter and Ozone on Childhood Allergic Rhinitis: China, Children, Homes, Health Study
by: Tianyi Chen, et al.
Published: (2026)

Management of Patients With Allergic Diseases in the Era of Biologics
by: Feng Lan, et al.
Published: (2025)

Transcriptomic Profiles of the Nasal Mucosa Following Birch Pollen Provocation Differ Between Birch Pollen‐Allergic and Non‐Allergic Individuals
by: Srinidhi Sudharson, et al.
Published: (2024)

Long‐Term Effect of Allergen Immunotherapy in Responder Local Allergic Rhinitis Patients: Symptom Control, and Prevention of Asthma and Allergic Sensitizations
by: Almudena Testera‐Montes, et al.
Published: (2025)

EQUAL ABPA Score 2024: A Tool to Measure Guideline Adherence for Managing Allergic Bronchopulmonary Aspergillosis
by: Inderpaul Singh Sehgal, et al.
Published: (2024)

Cluster Analysis Identifies Patients With Severe Eosinophilic Asthma Who Achieve Super‐Response and Remission With Mepolizumab
by: Danilo Di Bona, et al.
Published: (2024)

Circulating Type 2 Memory B Cell Frequency Is a Biomarker for Allergen Immunotherapy Efficacy in Patients With Allergic Rhinitis
by: Yue Ma, et al.
Published: (2026)

Budesonide Nasal Irrigation: An Effective Alternative Treatment for Allergic Rhinitis
by: Navarat Kasemsuk, et al.
Published: (2025)

Soybean Oil in Propofol Is Not Able to Induce Allergic Reactions
by: Deniz Eyice Karabacak, et al.
Published: (2024)

The Expanding Role of ILC2s in Allergic Airways Disease
by: Jafar Cain, et al.
Published: (2025)

On the Interpretation of Long‐Term Outcomes After Combined FESS and Mepolizumab in Severe CRSwNP
by: Francesca Pirola, et al.
Published: (2026)

Ficolin‐A Protects Against Allergic Asthma via Suppressing ILC2 ‐Drived Type 2 Inflammation
by: Yu‐ke Xie, et al.
Published: (2025)

East Meets West in Allergic Airway Disease: Insights From the EAACI Hong Kong Allergy School 2025
by: Xiaoling Yin, et al.
Published: (2025)

Response to Letter Regarding Article, “Efficacy and Safety of Omalizumab Combined With Allergen Immunotherapy in Children With Moderate to Severe Allergic Asthma”
by: Wenxin Shen, et al.
Published: (2025)

Effect of the Arg16Gly β 2 ‐Adrenergic Receptor Polymorphism on Long‐Term Mepolizumab Response and Clinical Remission in Severe Eosinophilic Asthma: A Genotype‐Stratified, Multicenter Study
by: Santi Nolasco, et al.
Published: (2025)